| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11737983 | MAIA PHARMS INC | Storage stable sincalide formulations |
Apr, 2038
(13 years from now) | |
| US11318100 | MAIA PHARMS INC | Storage stable sincalide formulations |
Apr, 2038
(13 years from now) | |
| US11110063 | MAIA PHARMS INC | Storage stable sincalide formulations |
Apr, 2038
(13 years from now) | |
Sincalide is owned by Maia Pharms Inc.
Sincalide contains Sincalide.
Sincalide has a total of 3 drug patents out of which 0 drug patents have expired.
Sincalide was authorised for market use on 22 November, 2022.
Sincalide is available in powder;intravenous dosage forms.
Sincalide can be used as diagnosis of gall bladder disorders by stimulating gallbladder contraction, as may be assessed by various methods of diagnostic imaging, or to obtain by duodenal aspiration a sample of concentrated bile for analysis, stimulate gallbladder contraction. as may be assessed by various methods of diagnostic imaging, or to obtain by duodenal aspiration a sample of concentrated bile for analysis, diagnostic imaging by accelerating the tran it ofa barium meal through the small bowel, thereby decreasing the time and extent of radiation associated with fluoroscopy and x-ray examination of the intestinal tract.
The generics of Sincalide are possible to be released after 20 April, 2038.
Drugs and Companies using SINCALIDE ingredient
Market Authorisation Date: 22 November, 2022
Treatment: Diagnosis of gall bladder disorders by stimulating gallbladder contraction, as may be assessed by various methods of diagnostic imaging, or to obtain by duodenal aspiration a sample of concentrated bi...
Dosage: POWDER;INTRAVENOUS
SINCALIDE family patents
